Stanley E. Waintraub, MD

Articles by Stanley E. Waintraub, MD

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

ByStanley E. Waintraub, MD,Donna McNamara, MD,Deena Mary Atieh Graham, MD,Andrew L. Pecora, MD,John Min, BS,Tommy Wu, BA,Hyun Gi Noh, MSC,Jacqueline Connors, RN, OCN,Ruth Pe Benito, MPH, BS,Kelly Choi, MD,Eric Schultz, BS,Stuart L. Goldberg, MD

December 20th 2017

Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.

Latest Updated Articles

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer
Published: December 20th 2017 | Updated:

Stanley E. Waintraub, MD

Articles by Stanley E. Waintraub, MD

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

Latest Updated Articles

Trending on AJMC

FDA Approves Use of Subcutaneous Pembrolizumab for NSCLC

FDA Approves Ruxolitinib Cream for Patients as Young as 2 Years With Atopic Dermatitis

Second Known Case of Concurrent ET, WM Raises Questions About Their Coexistence

Pirtobrutinib Shows Clinically Meaningful PFS Improvement in Frontline CLL

CSU More Burdensome in Female Patients, Especially in Midlife